HC-5404
Advanced Solid Tumors (enriched for RCC & gastric cancer)
Phase 1aCompleted - Monotherapy
Key Facts
Indication
Advanced Solid Tumors (enriched for RCC & gastric cancer)
Phase
Phase 1a
Status
Completed - Monotherapy
Company
About HiberCell
HiberCell is advancing a novel oncology platform focused on the Integrated Stress Response (ISR), a critical pathway cancer cells use to survive treatment and drive relapse. The company has three clinical-stage assets: HC-7366 and HC-5404, which target key ISR kinases, and odetiglucan, an immune modulator. With strategic collaborations and a leadership team of seasoned biotech executives, HiberCell is positioning itself to address significant unmet needs in resistant and metastatic cancers.
View full company profile